License Granted For BREST Lead-Cooled Reactor Build
Russian’s nuclear supervisor Rostechnadzor announced that its chairman, Alexey Aleshin, on February 10, signed a license for Siberian Chemical Combine to construct the world’s first experimental demonstration power plant with a lead-cooled fast neutron reactor.
The approval came after extensive delays. The license was first expected in December of 2019. It was postponed for June 2020, but that date also came and passed by with no license issued.
The BREST-OD-300 project is considered a key element of the pilot demonstration power complex that will also include a fabrication/refabrication processing facility for mixed nitride uranium/plutonium nuclear fuel. This will create a complex that not only produces electricity, but also creates new fuel from partially spent fuel removed from the reactor core.
A licence has been issued by the Russian nuclear regulator Rostechnadzor to the Siberian Chemical Combine for the construction of the BREST-OD-300 reactor at its site in Seversk, Russia. It will be the world's first experimental demonstration power unit featuring a lead-cooled fast neutron reactor.
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium
Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment
News provided by
Share this article
SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/
Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology s 2021 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 15-17, 2021.
Natera will have one oral and one poster presentation, each describing the clinical performance of Signatera in patients with colorectal cancer (CRC).